Bringing science and development together through news and analysis

  • Drug licences all for the poor, says Thai minister

Shares

The Thai minister of public health, Mongkol Na Songkhla, says the government's decision to issue compulsory licences on patented drugs was aimed solely at helping poor people, and that the country has borne "unfair" criticism.

In an interview in the journal Science (8 June), Mongkol explains that Thailand has limited itself to only issuing compulsory licences for five drugs at a time. This will minimise interference into research and development, innovation and investment, and still address the needs of the country's poor, he says.

He concedes that compulsory licensing was in part a tactic to encourage negotiation with drug companies. "They never wanted to sit down and talk with our committee. And right now it is easier for us to invite them."

Mongkol also thinks Thailand carried out their recent compulsory licensing too transparently, and that other countries simply go ahead with compulsory licensing without announcing their intentions.

He is still waiting to hear whether Abbott Laboratories — the makers of two AIDS drugs Thailand has issued compulsory licences for — will agree to a proposal to sell seven drugs at a lower price for non-commercial use.

Link to full article in Science

Republish
We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.